Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07468214
Recruiting Observational

Digitizing and Automating the Diagnostic Psychiatric Assessment Process

NCT07468214 · tracked via the Priya Life Science Spain tracker
Sponsor
Irene Lopez Armenteros
Phase
Observational
Started
2026-01-09
Last updated
2026-03-12

Condition(s) studied

Validation StudiesPsychiatric Diagnosis

Study summary

This is an observational study that will be responsible for the Spanish translation and cross-cultural adaptation, and validation of the Electronic Semi-Structured Psychiatric Interview for Children and Adolescents (EPSI-C), to examine, classify, prioritize, and diagnose patients.

Eligibility

Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
Accepted
Inclusion criteria: \- Families and children aged 6 to 17 with a mental health referral from primary care. Exclusion criteria: * Minors under state care without stable attachment figures to report clinical history. * Presence of global developmental disorder or moderate to severe intellectual disability. * Incomplete, inaccurate, or unclear medical data.

Primary outcome measure(s)

  • Child and adolescent psychiatric assessment — At baseline
    EPSI-C (Electronic Semi-Structured Psychiatric Interview for Children and Adolescents). A semi-structured diagnostic interview that assesses current episodes of psychopathology in children and adolescents aged 6 to 17 years according to the DSM-5 diagnostic criteria. The mental disorders assessed by the EPSI-C are: specific phobia, separation anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder (PTSD) and complex PTSD (according to ICD-11 criteria), major and persistent depression, manic/hypomanic episode, anorexia nervosa, bulimia nervosa, binge eating disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder, Tourette's disorder/tics, oppositional defiant disorder, and conduct disorder. It also includes screening for psychotic disorders and self-harm.

Trial sites (1)

FacilityCityRegionStatus
Plaza del Hospital Civil s/n, Pabellón 4, 1ª Planta Málaga Málaga Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07468214 on ClinicalTrials.gov ↗ ← All trials in Spain